News

A virtual summit on urothelial cancers is scheduled for October.

About 2% to 3% of patients with nonsmall cell lung cancer have EGFR exon 20 insertion mutations targeted by newly approved Rybrevant.

It is undoubtable that the role of telehealth technology has soared throughout the pandemic, achieving levels of adoption that were previously thought unattainable. However, appetites are changing drastically, the question is now; what role can telehealth play in emergency medicine?

Two of the biggest issues in healthcare, currently, are the lack of communication between prescribers and pharmacists, and the number of factors that prevent healthcare professionals from offering patient-centric services.

The prevalence of a single, prominent, chronic condition among Medicare beneficiaries is staggering: fully one-third of all Medicare beneficiaries have diabetes. As a result, 3.3 million Medicare beneficiaries take insulin.

Blue Cross Blue Shield Association study finds these rates are higher for Black and Hispanic women regardless of age. Reinforcements are a necessity to reduce racial disparities in maternal health.

Pace of vaccinations is slowing way down in the U.S., Sanofi, GSK report positive phase 2 results, the behavioral economics behind the vaccine lotteries, and going beyond the current crop of "spikecentric" vaccines.

Precision medicine is getting that much more precise. Today's FDA go-ahead is for a J&J drug that is designed to treat the 2% to 3% of NSCLC patients wiht EGFR exon 20 insertion mutations.

Briana Contreras, associate editor of Managed Healthcare Executive, speaks with Chris Evanguelidi, head of healthcare at Redpoint Global, for this week's episode of "Tuning In to the C-Suite" podcast. In this conversation, the two discussed the best practices for closing the healthcare experience gap and devising an effective patient engagement strategy through a more patient-centric health system.

CVS Health research shows $7,084 cost disadvantage to care that is not "concordant" with National Comprehensive Care Network guidelines.

Multiple sclerosis is dependably among the most expensive chronic diseases to treat, but there are ways to reduce the size of the bill.

Matthew Reynolds, PhD, vice president of real-world evidence at IQVIA, discusses his appreciation for telehealth and remote care, but feels over the next year or so we're going to be seeing more studies come out questioning if some telehealth is needed in certain areas. The discussion came from findings of a recent paper with the National Pharmaceutical Council on how COVID-19 affected real-world data and research.

A small fraction of those who were eligible under previous U.S. Preventive Services Task Force recommendations were screened with low-dose CT scans. New recommendations will make an additional 6.4 million Americans eligible, but a number of barriers to screening remain.

Amy Abernethy, M.D., Ph.D., hematologist/oncologist and palliative medicine physician and former principal deputy commissioner of the FDA, discusses how the agency handled COVID-19 and what lessons learned will help going forward. Abernethy also addresses if she feels there are enough safeguards of the FDA's independence in place, and reflects on the open FDA commissioner position.

Panelists at 2021 ISPOR say price shouldn't be barrier. Suggestions include steep payment discounts if therapies don't meet outcome goals and regulators removing withdrawing approvals if the therapy doesn't work.

PBMs say exclusions are important for negotiating lower prices on behalf of health plans and members. Some payer and provider groups say they interfere with patient access to medicines.

In this final part of a two-part video series, Briana Contreras, associate editor of Managed Healthcare Executive spoke with Dr. Sheldon Fields Associate Dean for Equity Inclusion and Research Professor in the College of Nursing at Penn State University, about the ongoing All of Us research program. All of Us is an initiative through partners of the National Black Nurses Association, which Fields is vice president of, and the National Institutes of Health that invites one million people across the U.S. to help build one of the most diverse health databases in U.S. history.

In this first of a two-part video series, Briana Contreras, associate editor of Managed Healthcare Executive spoke with Dr. Sheldon Fields Associate Dean for Equity Inclusion and Research Professor in the College of Nursing at Penn State University, about the ongoing All of Us research program. All of Us is an initiative through partners of the National Black Nurses Association, which Fields is vice president of, and the National Institutes of Health that invites one million people across the U.S. to help build one of the most diverse health databases in U.S. history.

OptumRx had identified pegcetacoplan as one of the top 5 drugs in the pipeline this year.

Companies are forming and investment dollars are pouring in. Can these services make mental healthcare more accessible and affordable as the pandemic leaves depression and anxiety in its wake?

Sanofi and GlaxoSmithKline’s joint COVID-19 vaccine candidate achieved 95% to 100% seroconversion in a Phase 2 study.

It shouldn’t be just about QALYs and cost. An ISPOR panel today discussed how best to incorporate the patient perspective into value assessment.

Dr. Vivian Lee of Verily Life Sciences addresses if value-based care programs have steered U.S healthcare away from the problems of fee-for-service at a virtual ISPOR meeting today. Lee also shares her thoughts on if the pandemic changed her views of American healthcare.

"COVID. KNOW MORE," is an innovative, timely new initiative empowering Black Americans with the latest information, resources, and updates on COVID-19.

The model has put the patient at the center of healthcare.

Federally Qualified Health Centers have been the safety net for individuals in need for decades. However, even with increasing demand for their services – tripling the number of patients served to more than 28 million since 2000 – FQHCs are not immune from challenges stemming from the pandemic.

Too many study volunteers randomized to the 325-mg dose switched to the 81-mg one to settle the dosage issue But ADAPTABLE is still being celebrated as the kind of "pragmatic study'' that can be a less expensive, more realistic version of the RCT.

The pandemic revealed the fragility, vulnerabilities and unique dangers of working in the healthcare setting. Chief among these was the eroded ability to service patients when there were staff availability issues.

A 13% decline in the past year continues downward. Some of the decline might be explained by pandemic-related drop in healthcare utilization.